A U.S. Patent for “Delivery Methods and Compositions for Nuclease-Mediated Genome Engineering” was awarded to Sangamo Therapeutics on October 22nd, 2019. The present invention is a method of introducing a donor nucleic acid molecule into an isolated cell, the method comprising: administering to the cell at least one adeno-associated virus (AAV) vector comprising a donor nucleic acid molecule in the presence of at least one inhibitor of Platelet-derived growth factor receptor under conditions sufficient to increase efficiency of viral delivery to the cell, wherein the AAV vector has an AAV6 capsid. Learn More